AC Immune SA logo

ACIU

AC Immune SA

$3.28

Earnings Summary

Revenue
$0Mn
Net Profits
$-19.64Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

AC Immune SA’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2022. On a quarterly growth basis, AC Immune SA has generated NaN% jump in its revenue since last 3-months.

Net Profits:

AC Immune SA’s net profit fell -3.01% since last year same period to $-19.64Mn in the Q2 2022. On a quarterly growth basis, AC Immune SA has generated -4.22% fall in its net profits since last 3-months.

Net Profit Margins:

AC Immune SA’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2022. On a quarterly growth basis, AC Immune SA has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AC Immune SA post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

AC Immune SA’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -8.7% fall from last quarter’s estimates.

EPS Estimate Current Year:

AC Immune SA’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the AC Immune SA post its Q2 2022 earnings

Earning Per Share (EPS)
-0.23
Return on Assets (ROA)
-0.24
Return on Equity (ROE)
-0.39
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

AC Immune SA’s earning per share (EPS) jumped 11.54% since last year same period to -0.23 in the Q2 2022. This indicates that the AC Immune SA has generated 11.54% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. AC Immune SA’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. AC Immune SA’s return on equity (ROE) stands at -0.39.

Dividend Per Share (DPS):

AC Immune SA declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-30
-0.23
-0.23
0%
2022-03-31
-0.22
-0.23
-4.55%

Company Information

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.

Organisation
AC Immune SA
Headquarters
Lausanne, Vaud, Switzerland
Employees
137
Industry
Health Technology
CEO
Andrea Pfeifer